Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2017. Poster
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis. ASH 2017. Poster
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis
Results From Ongoing Phase 1/2 Trial of SL-401 as Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with Minimal Residual Disease (MRD). ASH 2017. Poster
Ongoing Phase 2 Clinical Trial of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Stage 1 and Stage 2 Results. EHA 2017.
Ongoing Phase 2 Clinical Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Stage 1 and Stage 2 Results. EHA 2017. Clinical – Poster
Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results
Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results. ESMO 2017. Poster
Results From Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2016
Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2016. Clinical – Oral Presentation
Phase 2 Trial of SL-701, a Novel Immunotherapy Comprised of Synthetic Short Peptides Against GBM Targets IL-13Rα2, EphA2, and Survivin, in Adults With Second-Line Recurrent GBM: Interim Results
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM: Interim results. SNO 2016. Oral Presentation
Results From Ongoing Phase 2 Trial of SL-401 as Consolidation Therapy in Patients With Acute Myeloid Leukemia (AML) in Remission With High Relapse Risk Including Minimal Residual Disease (MRD)
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). ASH 2016. Clinical – Oral Presentation
Results From Ongoing Phase 2 Trial of SL-401 in Patients With Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. ASH 2016
Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia. ASH 2016. Clinical – Poster
Results From Ongoing Phase 1/2 Trial of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Clinical — On-line Abstract